120,101 Shares in Simulations Plus, Inc. $SLP Acquired by Tudor Investment Corp ET AL

Key Points

• Tudor Investment Corp et al bought a new position of 120,101 shares of Simulations Plus in Q3, worth about $1.81 million and representing roughly 0.60% ownership.
• Simulations Plus beat Q2 expectations (EPS $0.35 vs. $0.27; revenue $24.29M vs. $21.66M) and management highlighted AI-driven biosimulation opportunities alongside growing backlog and improving margins.
• Despite the quarter beat, FY2026 EPS guidance was cut to $0.75–$0.85 and several analysts trimmed ratings/targets, leaving a consensus Hold rating with a $24.40 price target while the stock trades near $13.04.

Tudor Investment Corp ET AL bought a new position in shares of Simulations Plus, Inc. (NASDAQ:SLP - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 120,101 shares of the technology company's stock, valued at approximately $1,810,000. Tudor Investment Corp ET AL owned about 0.60% of Simulations Plus as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Simulations Plus by 4.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,493 shares of the technology company's stock worth $233,000 after purchasing an additional 390 shares during the last quarter. Prudential Financial Inc. increased its position in Simulations Plus by 5.7% during the second quarter. Prudential Financial Inc. now owns 17,213 shares of the technology company's stock worth $300,000 after buying an additional 930 shares during the period. Invesco Ltd. increased its position in Simulations Plus by 3.8% during the second quarter. Invesco Ltd. now owns 36,452 shares of the technology company's stock worth $636,000 after buying an additional 1,323 shares during the period. Raymond James Financial Inc. acquired a new position in Simulations Plus during the second quarter worth approximately $25,000. Finally, US Bancorp DE increased its position in Simulations Plus by 32.5% during the third quarter. US Bancorp DE now owns 6,167 shares of the technology company's stock worth $93,000 after buying an additional 1,513 shares during the period. Hedge funds and other institutional investors own 78.08% of the company's stock.

Analysts Set New Price Targets

Several research analysts have commented on the company. Zacks Research lowered Simulations Plus from a "strong-buy" rating to a "hold" rating in a research report on Monday, February 2nd. TD Cowen cut their price target on Simulations Plus from $19.00 to $16.00 and set a "hold" rating on the stock in a research report on Friday. BTIG Research lowered Simulations Plus from a "buy" rating to a "neutral" rating in a research report on Thursday, December 18th. Wall Street Zen lowered Simulations Plus from a "buy" rating to a "hold" rating in a research report on Saturday, April 4th. Finally, Citigroup reaffirmed a "market perform" rating on shares of Simulations Plus in a research report on Tuesday, January 6th. Three equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $24.40.

Simulations Plus Stock Performance

NASDAQ:SLP opened at $13.04 on Monday. The firm has a market cap of $262.72 million, a P/E ratio of -4.17 and a beta of 1.19. The stock's 50 day simple moving average is $12.48 and its 200-day simple moving average is $15.98. Simulations Plus, Inc. has a 12-month low of $11.09 and a 12-month high of $36.45.

Simulations Plus (NASDAQ:SLP - Get Free Report) last released its earnings results on Thursday, April 9th. The technology company reported $0.35 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.27 by $0.08. The business had revenue of $24.29 million for the quarter, compared to analyst estimates of $21.66 million. Simulations Plus had a positive return on equity of 16.21% and a negative net margin of 77.96%. Research analysts forecast that Simulations Plus, Inc. will post 1.09 EPS for the current fiscal year.

Simulations Plus News Roundup

Here are the key news stories impacting Simulations Plus this week:

• Positive Sentiment: Q2 results beat expectations — SLP reported $0.35 EPS vs. $0.27 consensus and revenue of $24.29M vs. $21.66M expected; software revenue grew and management provided supporting slides/press release. Simulations Plus Reports Second Quarter Fiscal 2026 Financial Results
• Positive Sentiment: Management highlights growth drivers & AI opportunity — company commentary and coverage emphasize an improving biosimulation outlook driven by AI adoption, which supports longer-term revenue potential. Simulations Plus jumps on earnings beat, sees AI boosting biosimulation outlook
• Positive Sentiment: Backlog and margin trends supportive — coverage notes backlog growth and expanding margins across software and services, which can underpin future revenue and profitability improvements. Simulations Plus Q2 Earnings & Revenues Beat, Jump Y/Y, Shares Soar
• Neutral Sentiment: Full earnings call/transcript and slides now available for deeper diligence — read the call transcript and slide deck for management detail on bookings, segment trends, and AI initiatives. Simulations Plus (SLP) Q2 2026 Earnings Transcript
• Negative Sentiment: FY2026 EPS guidance trimmed — company updated FY26 EPS guidance to $0.75–$0.85 vs. consensus ~$1.01, a clear downward revision that can pressure valuation and near-term sentiment. Guidance coverage
• Negative Sentiment: Analyst target cut and rating — TD Cowen lowered its price target from $19 to $16 and set a “hold,” which reduces near-term upside implied by Street estimates and may temper momentum. Benzinga coverage of TD Cowen note

About Simulations Plus

Simulations Plus, Inc NASDAQ: SLP specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company's flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.

Want to see what other hedge funds are holding SLP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Simulations Plus, Inc. (NASDAQ:SLP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.